FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376629679> ?p ?o ?g. }

• W4376629679 endingPage "101233" @default.
• W4376629679 startingPage "101233" @default.
• W4376629679 abstract "PurposeTo present the long-term results of intraoperative radiation therapy (IORT) for early breast cancer using a nondedicated linear accelerator.Methods and MaterialsThe eligibility criteria were biopsy-proven invasive carcinoma, age ≥40 years, tumor size ≤3 cm, and N0M0. We excluded multifocal lesions and sentinel lymph node involvement. All patients had previously undergone breast magnetic resonance imaging. Breast-conserving surgery with margins and sentinel lymph node evaluation using frozen sections were performed in all cases. If there were no margins or involved sentinel lymph nodes, the patient was transferred from the operative suite to the linear accelerator room, where IORT was delivered (21 Gy).ResultsA total of 209 patients who were followed up for ≥1.5 years from 2004 to 2019 were included. The median age was 60.3 years (range, 40-88.6), and the mean pT was 1.3 cm (range, 0.2-4). There were 90.5% pN0 cases (7.2% of micrometastases and 1.9% of macrometastases). Ninety-seven percent of the cases were margin free. The rate of lymphovascular invasion was 10.6%. Twelve patients were negative for hormonal receptors, and 28 patients were HER2 positive. The median Ki-67 index was 29% (range, 0.1-85). Intrinsic subtype stratification was as follows: luminal A, 62.7% (n = 131); luminal B, 19.1% (n = 40); HER2 enriched 13.4% (n = 28); and triple negative, 4.8% (n = 10). Within the median follow-up of 145 months (range, 12.8-187.1), the 5-year, 10-year, and 15-year overall survival rates were 98%, 94.7%, and 88%, respectively. The 5-year, 10-year, and 15-year disease-free rates were 96.3%, 90%, and 75.6%, respectively. The 15-year local recurrence-free rate was 76%. Fifteen local recurrences (7.2%) occurred throughout the follow-up period. The mean time to local recurrence was 145 months (range, 12.8-187.1). As a first event, 3 cases of lymph node recurrence, 3 cases of distant metastasis, and 2 cancer-related deaths were recorded. Tumor size >1 cm, grade III, and lymphovascular invasion were identified as risk factors.ConclusionsDespite approximately 7% of recurrences, we may infer that IORT may still be a reasonable option for selected cases. However, these patients require a longer follow-up as recurrences may occur after 10 years. To present the long-term results of intraoperative radiation therapy (IORT) for early breast cancer using a nondedicated linear accelerator. The eligibility criteria were biopsy-proven invasive carcinoma, age ≥40 years, tumor size ≤3 cm, and N0M0. We excluded multifocal lesions and sentinel lymph node involvement. All patients had previously undergone breast magnetic resonance imaging. Breast-conserving surgery with margins and sentinel lymph node evaluation using frozen sections were performed in all cases. If there were no margins or involved sentinel lymph nodes, the patient was transferred from the operative suite to the linear accelerator room, where IORT was delivered (21 Gy). A total of 209 patients who were followed up for ≥1.5 years from 2004 to 2019 were included. The median age was 60.3 years (range, 40-88.6), and the mean pT was 1.3 cm (range, 0.2-4). There were 90.5% pN0 cases (7.2% of micrometastases and 1.9% of macrometastases). Ninety-seven percent of the cases were margin free. The rate of lymphovascular invasion was 10.6%. Twelve patients were negative for hormonal receptors, and 28 patients were HER2 positive. The median Ki-67 index was 29% (range, 0.1-85). Intrinsic subtype stratification was as follows: luminal A, 62.7% (n = 131); luminal B, 19.1% (n = 40); HER2 enriched 13.4% (n = 28); and triple negative, 4.8% (n = 10). Within the median follow-up of 145 months (range, 12.8-187.1), the 5-year, 10-year, and 15-year overall survival rates were 98%, 94.7%, and 88%, respectively. The 5-year, 10-year, and 15-year disease-free rates were 96.3%, 90%, and 75.6%, respectively. The 15-year local recurrence-free rate was 76%. Fifteen local recurrences (7.2%) occurred throughout the follow-up period. The mean time to local recurrence was 145 months (range, 12.8-187.1). As a first event, 3 cases of lymph node recurrence, 3 cases of distant metastasis, and 2 cancer-related deaths were recorded. Tumor size >1 cm, grade III, and lymphovascular invasion were identified as risk factors. Despite approximately 7% of recurrences, we may infer that IORT may still be a reasonable option for selected cases. However, these patients require a longer follow-up as recurrences may occur after 10 years." @default.
• W4376629679 created "2023-05-17" @default.
• W4376629679 creator A5012807139 @default.
• W4376629679 creator A5019455860 @default.
• W4376629679 creator A5037716547 @default.
• W4376629679 creator A5057477338 @default.
• W4376629679 creator A5059349473 @default.
• W4376629679 creator A5065463954 @default.
• W4376629679 creator A5067097657 @default.
• W4376629679 creator A5071477903 @default.
• W4376629679 creator A5075391311 @default.
• W4376629679 creator A5086305901 @default.
• W4376629679 date "2023-09-01" @default.
• W4376629679 modified "2023-10-18" @default.
• W4376629679 title "Long-Term Results of Intraoperative Radiation Therapy for Early Breast Cancer Using a Nondedicated Linear Accelerator" @default.
• W4376629679 cites W1872847304 @default.
• W4376629679 cites W1986864198 @default.
• W4376629679 cites W1989726860 @default.
• W4376629679 cites W2006916290 @default.
• W4376629679 cites W2025968998 @default.
• W4376629679 cites W2083399503 @default.
• W4376629679 cites W2083825568 @default.
• W4376629679 cites W2096499183 @default.
• W4376629679 cites W2097823108 @default.
• W4376629679 cites W2100025800 @default.
• W4376629679 cites W2103608035 @default.
• W4376629679 cites W2128585633 @default.
• W4376629679 cites W2137693556 @default.
• W4376629679 cites W2146522000 @default.
• W4376629679 cites W2164602611 @default.
• W4376629679 cites W2166067039 @default.
• W4376629679 cites W2408991739 @default.
• W4376629679 cites W2507403532 @default.
• W4376629679 cites W2519353639 @default.
• W4376629679 cites W2560594661 @default.
• W4376629679 cites W2577994305 @default.
• W4376629679 cites W2620389466 @default.
• W4376629679 cites W2677570205 @default.
• W4376629679 cites W2735927054 @default.
• W4376629679 cites W2740659413 @default.
• W4376629679 cites W2767528733 @default.
• W4376629679 cites W2789698864 @default.
• W4376629679 cites W2895926103 @default.
• W4376629679 cites W2944375432 @default.
• W4376629679 cites W2952817283 @default.
• W4376629679 cites W2992619229 @default.
• W4376629679 cites W2993667428 @default.
• W4376629679 cites W3016251265 @default.
• W4376629679 cites W3022548009 @default.
• W4376629679 cites W3067502370 @default.
• W4376629679 cites W3113157419 @default.
• W4376629679 cites W3155789907 @default.
• W4376629679 cites W3198790208 @default.
• W4376629679 doi "https://doi.org/10.1016/j.adro.2023.101233" @default.
• W4376629679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37408678" @default.
• W4376629679 hasPublicationYear "2023" @default.
• W4376629679 type Work @default.
• W4376629679 citedByCount "0" @default.
• W4376629679 crossrefType "journal-article" @default.
• W4376629679 hasAuthorship W4376629679A5012807139 @default.
• W4376629679 hasAuthorship W4376629679A5019455860 @default.
• W4376629679 hasAuthorship W4376629679A5037716547 @default.
• W4376629679 hasAuthorship W4376629679A5057477338 @default.
• W4376629679 hasAuthorship W4376629679A5059349473 @default.
• W4376629679 hasAuthorship W4376629679A5065463954 @default.
• W4376629679 hasAuthorship W4376629679A5067097657 @default.
• W4376629679 hasAuthorship W4376629679A5071477903 @default.
• W4376629679 hasAuthorship W4376629679A5075391311 @default.
• W4376629679 hasAuthorship W4376629679A5086305901 @default.
• W4376629679 hasBestOaLocation W43766296791 @default.
• W4376629679 hasConcept C121608353 @default.
• W4376629679 hasConcept C126322002 @default.
• W4376629679 hasConcept C126838900 @default.
• W4376629679 hasConcept C141071460 @default.
• W4376629679 hasConcept C142724271 @default.
• W4376629679 hasConcept C143409427 @default.
• W4376629679 hasConcept C179671157 @default.
• W4376629679 hasConcept C2775934546 @default.
• W4376629679 hasConcept C2777757722 @default.
• W4376629679 hasConcept C2778740770 @default.
• W4376629679 hasConcept C2779013556 @default.
• W4376629679 hasConcept C2779720271 @default.
• W4376629679 hasConcept C2780212769 @default.
• W4376629679 hasConcept C2780849966 @default.
• W4376629679 hasConcept C2781467025 @default.
• W4376629679 hasConcept C2989005 @default.
• W4376629679 hasConcept C509974204 @default.
• W4376629679 hasConcept C530470458 @default.
• W4376629679 hasConcept C71924100 @default.
• W4376629679 hasConceptScore W4376629679C121608353 @default.
• W4376629679 hasConceptScore W4376629679C126322002 @default.
• W4376629679 hasConceptScore W4376629679C126838900 @default.
• W4376629679 hasConceptScore W4376629679C141071460 @default.
• W4376629679 hasConceptScore W4376629679C142724271 @default.
• W4376629679 hasConceptScore W4376629679C143409427 @default.
• W4376629679 hasConceptScore W4376629679C179671157 @default.
• W4376629679 hasConceptScore W4376629679C2775934546 @default.
• W4376629679 hasConceptScore W4376629679C2777757722 @default.

• next